Botulinum A toxin Nuceiva Active substance Botulinum A toxinDomain Neurological disordersReason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)Main indication Other neurological disordersExtended indication Nuceiva is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. 1. Product Proprietary name NuceivaManufacturer EvolusMechanism of action NeurotoxinRoute of administration IntramuscularTherapeutical formulation InjectionBudgetting framework Extramural (GVS) 2. Registration Registration route Centralised (EMA)Type of trajectory Normal trajectoryParticularity New therapeutical formulationSubmission date August 2017Expected Registration September 2019Orphan drug NoRegistration phase RegisteredAdditional comments Positieve CHMP-opinie april 2019. Geregistreerd per 27/09/2019. 3. Therapeutic value Therapeutic value No judgementDuration of treatment Not found 4. Expected patient volume per year There is currently nothing known about the expected patient volume. 5. Expected cost per patient per year There is currently nothing known about the expected cost. 6. Potential total cost per year There is currently nothing known about the possible total cost. 7. Off label use There is currently nothing known about off label use. 8. Indication extension There is currently nothing known about indication extensions. 9. Other information There is currently no futher information available.